Anand Mehra - Aerie Pharmaceuticals Director
| AERIDelisted Stock | USD 15.25 0.01 0.07% |
Director
Dr. Anand Mehra M.D. is Director of Aerie Pharmaceuticals Inc. since August 2010 . Dr. Mehra has twelve years of experience as a management consultant and biotechnology investor and currently serves as a General Partner at Sofinnova Ventures which he joined in 2007 as a principal a biotechnology focused investment firm specializing in clinicalstage pharmaceutical companies. Prior to joining Sofinnova Ventures Dr. Mehra was employed at JP Morgan Partners and consulted at McKinsey and Company. Dr. Mehra currently serves as a member of the boards of directors of several private companies and two public companies Marinus Pharmaceuticals Inc. and Spark Therapeutics Inc since 2010.
| Age | 39 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 919 237-5300 |
| Web | www.aeriepharma.com |
Anand Mehra Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anand Mehra against Aerie Pharmaceuticals stock is an integral part of due diligence when investing in Aerie Pharmaceuticals. Anand Mehra insider activity provides valuable insight into whether Aerie Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Aerie Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aerie Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anand Mehra over six months ago Acquisition by Anand Mehra of 3300 shares of Marinus Pharmaceuticals subject to Rule 16b-3 |
Aerie Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0459) % which means that it has lost $0.0459 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.5501) %, meaning that it created substantial loss on money invested by shareholders. Aerie Pharmaceuticals' management efficiency ratios could be used to measure how well Aerie Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 234.53 M in liabilities with Debt to Equity (D/E) ratio of 9.41, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals has a current ratio of 2.55, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Aerie Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aerie Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aerie Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aerie to invest in growth at high rates of return. When we think about Aerie Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Chig Cheng | HUTCHMED DRC | 47 | |
| Hideto Mitamura | HUTCHMED DRC | 64 | |
| Toshihiro Ohno | HUTCHMED DRC | 58 | |
| Ellen Jewett | JetBlue Airways Corp | 58 | |
| Koosh Patel | JetBlue Airways Corp | N/A | |
| Panagiotis Laskaridis | Aegean Airlines SA | N/A | |
| Gene Burleson | SunLink Health Systems | 77 | |
| David Checketts | JetBlue Airways Corp | 60 | |
| Yunian Li | Jutal Offshore Oil | 55 | |
| Stanley McChrystal | JetBlue Airways Corp | 62 | |
| Takayoshi Ikeda | HUTCHMED DRC | N/A | |
| Vittorio Pisante | Aegean Airlines SA | 47 | |
| NikolaosGeorgios Nanopoulos | Aegean Airlines SA | N/A | |
| Akihiko Hiraoka | HUTCHMED DRC | 58 | |
| John Cox | Repligen | 54 | |
| Masato Tamaki | HUTCHMED DRC | 58 | |
| Ke Lin | Jutal Offshore Oil | 54 | |
| Michifumi Tabuchi | HUTCHMED DRC | N/A | |
| Kenji Ohta | HUTCHMED DRC | 57 | |
| Anastasios David | Aegean Airlines SA | 43 | |
| Iakovos Georganas | Aegean Airlines SA | 85 | |
Management Performance
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 |
Aerie Pharmaceuticals Leadership Team
Elected by the shareholders, the Aerie Pharmaceuticals' board of directors comprises two types of representatives: Aerie Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerie. The board's role is to monitor Aerie Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aerie Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerie Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wanda Francies, Head HR | ||
| Vicente Anido, Chairman and CEO | ||
| Julie McHugh, Independent Director | ||
| Peter Lang, Chief Officer | ||
| Marvin Garrett, Head Assurance | ||
| Casey Kopczynski, Co-Founder and Chief Scientific Officer | ||
| Benjamin McGraw, Independent Director | ||
| Craig Skenes, Head Devel | ||
| Thomas Mitro, Pres and COO | ||
| Eric Carlson, Vice President - Research & Development | ||
| Raj Kannan, Principal CEO | ||
| Jeffrey CPA, VP Officer | ||
| Deanne Melloy, Vice President - Marketing | ||
| Michelle Senchyna, Head Operations | ||
| David Gryska, Independent Director | ||
| Murray Goldberg, Board Member | ||
| Richard Lewis, Chief Medical Officer | ||
| John LaRocca, General Counsel | ||
| Richard Rubino, CFO | ||
| John Esq, G Sec | ||
| Anand Mehra, Director | ||
| Gerald Cagle, Director | ||
| Richard Croarkin, Independent Director | ||
| Michael Toit, Independent Director | ||
| Tori Arens, Vice President - Drug Product Manufacturing | ||
| Carolyn McAuliffe, Director Communications | ||
| Geoffrey Duyk, Director |
Aerie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aerie Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 | |||
| Profit Margin | (0.17) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 918.14 M | |||
| Shares Outstanding | 49.42 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Number Of Shares Shorted | 1.52 M | |||
| Price To Earning | (19.00) X |
Pair Trading with Aerie Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aerie Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aerie Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aerie Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aerie Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aerie Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aerie Pharmaceuticals to buy it.
The correlation of Aerie Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aerie Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aerie Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aerie Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Aerie Stock
If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |